Franklin Lakes- 12 August 2024- BD announced that it has named Michael Feld executive vice president and president of the Life Sciences segment, effective Aug. 20, 2024, and will serve as a member of the Executive Leadership Team. He succeeds Dave Hickey, who retired from BD last month after 10 years with the company.
Feld joins BD from Veralto, a spin-off of Danaher, where he was most recently president of Hach, a global leader in water quality products. Before that, Feld held several senior roles at Danaher, including senior vice president and general manager of Cepheid Europe, and served as president of several other Danaher businesses including Mammotome, XOS and Dover Motion, all focused on strategic planning, superior quality, associate development and cultural progression.
“Mike’s expertise in applying commercial and operational excellence principles to deliver impactful results, coupled with his experience in diagnostic solutions, position him well to lead our Life Sciences segment,” said Tom Polen, chairman, CEO and president of BD.
Also Read: Mike Shannon Elected to Mayo Clinic Board of Trustees
As president of the BD Life Sciences segment, which includes Biosciences, Diagnostics Solutions and Specimen Management, Feld will be responsible for an organization that is delivering innovative advancements from discovery to diagnosis. Under his leadership, BD Life Sciences will continue to focus on developing solutions around smart, connected, end-to-end workflows, specimen collection and diagnostics at new care settings, which will improve the diagnosis and treatment of chronic conditions.
